Agfa HealthCare has signed an agreement with Curagita Holding AG to acquire all the shares of its subsidiary Insight Agents GmbH, a German-based developer and producer of generic contrast media.
Agfa HealthCare has signed an agreement with Curagita Holding AG to acquire all the shares of its subsidiary Insight Agents GmbH, a German-based developer and producer of generic contrast media. Agfa expects to pay about 10 million Euros for the contrast media firm in a deal that the Belgian company is framing as an important strategic step towards future growth opportunities. Insight Agents makes generic contrast media, including the MR contrast agent Magnegita (gadopentetate dimeglumine), a generic form of Magnevist, and Iopamigita (Iopamidol), a generic form of Isovue. Insight’s contrast media are logical additions to Agfa’s portfolio of film, chemicals, and printers, according to Christian Reinaudo, president of Agfa HealthCare. They will be distributed through the company’s extensive logistics and distribution network, he said.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Enhanced Mobile CT System with High-Resolution Photon-Counting Technology
July 15th 2024Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.